奧氮平致代謝紊亂和心血管疾病研究進展
發(fā)布時間:2018-10-09 12:11
【摘要】:正抗精神病藥物是治療精神分裂癥(schizophrenia,SZ)及其他精神病性障礙的最主要手段,目前臨床廣泛使用的第二代抗精神病藥物(second generation antipsychotics,SGA),尤其是奧氮平,能夠引起以肥胖和胰島素抵抗(insulin resistance,IR)為主的代謝紊亂(metabolic disorder),顯著增加2型糖尿病和心血管疾病(cardiovascular disease,CVD)的風險[1-3]。研究發(fā)現(xiàn)長期使用奧氮平的患者,代謝紊亂和CVD的發(fā)生率是普通人群2~3倍[4],因此近年來,奧氮平致代謝紊亂和CVD的機制備受關注。代謝紊亂是CVD的重要危險因素,而近期研究發(fā)現(xiàn)奧氮平所致代謝紊
[Abstract]:Positive antipsychotics are the most important treatment for schizophrenia (schizophrenia,SZ) and other psychotic disorders. At present, the second generation antipsychotic drug (second generation antipsychotics,SGA), especially olanzapine, is widely used in clinical practice. Metabolic disorders such as obesity and insulin resistance (insulin resistance,IR) are associated with (metabolic disorder), significantly increasing the risk of type 2 diabetes and cardiovascular disease (cardiovascular disease,CVD) [1-3]. It has been found that the incidence of metabolic disorder and CVD in patients with olanzapine for a long time is three times higher than that in the general population. Therefore, the mechanism of metabolic disorder and CVD induced by olanzapine has attracted much attention in recent years. Metabolic disorder is an important risk factor for CVD, and recent studies have found that the metabolism of olanzapine is orderly.
【作者單位】: 上海交通大學醫(yī)學院附屬精神衛(wèi)生中心;Division
【基金】:國家自然科學基金面上項目(編號:81171266,81271481) 上海市重性精神病重點實驗室(編號:13dz2260500) 上海市科技創(chuàng)新計劃(編號:11140900400)201108
【分類號】:R54;R749
[Abstract]:Positive antipsychotics are the most important treatment for schizophrenia (schizophrenia,SZ) and other psychotic disorders. At present, the second generation antipsychotic drug (second generation antipsychotics,SGA), especially olanzapine, is widely used in clinical practice. Metabolic disorders such as obesity and insulin resistance (insulin resistance,IR) are associated with (metabolic disorder), significantly increasing the risk of type 2 diabetes and cardiovascular disease (cardiovascular disease,CVD) [1-3]. It has been found that the incidence of metabolic disorder and CVD in patients with olanzapine for a long time is three times higher than that in the general population. Therefore, the mechanism of metabolic disorder and CVD induced by olanzapine has attracted much attention in recent years. Metabolic disorder is an important risk factor for CVD, and recent studies have found that the metabolism of olanzapine is orderly.
【作者單位】: 上海交通大學醫(yī)學院附屬精神衛(wèi)生中心;Division
【基金】:國家自然科學基金面上項目(編號:81171266,81271481) 上海市重性精神病重點實驗室(編號:13dz2260500) 上海市科技創(chuàng)新計劃(編號:11140900400)201108
【分類號】:R54;R749
【相似文獻】
相關期刊論文 前10條
1 張德亮,孟慶玲;奧氮平致嚴重低血鉀1例[J];中國臨床藥學雜志;2000年05期
2 吳向平,范小琴;超量服奧氮平搶救成功1例[J];上海精神醫(yī)學;2004年05期
3 ;奧氮平和利培酮不宜用于老年癡呆患者[J];藥物不良反應雜志;2004年05期
4 趙黎君;韓耀靜;羅烈嵐;;奧氮平與利培酮治療癡呆患者的行為和精神癥狀的對照研究[J];中國民康醫(yī)學;2006年05期
5 王德林;孟慶豐;;國產奧氮平對腦器質性精神障礙的療效分析[J];中國神經免疫學和神經病學雜志;2008年01期
6 何凡;鄭毅;;奧氮平治療難治性Tourette綜合征1例[J];臨床精神醫(yī)學雜志;2008年06期
7 毛星;劉洪秋;陳玉輝;;奧氮平與阿立哌唑治療難治性精神分裂癥70例的對照研究[J];中國民康醫(yī)學;2010年11期
8 毛星;陳玉輝;劉洪秋;;奧氮平治療難治性精神分裂癥45例的療效分析[J];中國民康醫(yī)學;2010年13期
9 任季冬;戢彬;蔡旭明;;奧氮平與利培酮治療老年期精神障礙的對照研究[J];檢驗醫(yī)學與臨床;2010年09期
10 楊雀屏;張恒;包pせ,
本文編號:2259290
本文鏈接:http://www.sikaile.net/yixuelunwen/jsb/2259290.html
最近更新
教材專著